Item 8.01. Other Events.

On January 19, 2022, Spero Therapeutics, Inc. (the "Company") announced that the Biomedical Advanced Research and Development Authority (BARDA), added, and exercised, a new option on the contract originally awarded to the Company in 2018. The new option increases the total amount of committed funding by $12.9 million to $46.9 million, increasing the total potential contract value to $59.7 million. As previously announced, the Defense Threat Reduction Agency (DTRA) is providing up to approximately $10.0 million, in addition to the total potential award from BARDA, to cover the cost of the nonclinical biodefense aspects of the collaboration program for tebipenem HBr. The additional $12.9 million option is expected to provide support for a clinical trial and related activities for orally administered tebipenem pivoxil's use in treating pediatric patients with complicated urinary tract infections, including acute pyelonephritis.

Item 9.01. Financial Statements and Exhibits.




(d)  Exhibits.



99.1       Press Release, dated January 19, 2022.

104      Cover Page Interactive Data File (embedded within the Inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses